| Project/Area Number |
16K09823
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
西條 康夫 新潟大学, 医歯学系, 教授 (10270828)
小澤 拓也 新潟大学, 医歯学系, 講師 (70467075)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | エリスロポエチン / ヘパリン親和性 / ヘパリン結合ドメイン / 血栓 / 組織保護 / 血管障害 / 細胞外マトリックス / サイトカイン |
|---|
| Outline of Final Research Achievements |
Erythropoietin (EPO) has been used as an erythropoietic stimulant, and it is also shows tissue-protective and regenerative effects. We synthesized a hybrid molecule of EPO ; heparin affinity erythropoietin (HEPO), and studied the biological characteristics of this novel EPO derivative. Human HEPO (rhHEPO) shows not only long-acting erythropoietic activity, but also antiangiogenic effect. This novel EPO derivative (HEPO) may have advantages to act on thrombosis and hemostasis, in addition to tissue-protective and anti-tumor effects.
|
| Academic Significance and Societal Importance of the Research Achievements |
HEPOは赤血球造血作用を保ちつつ、ヘパリン親和性が付与されたことにより、長時間造血作用を示すとともに、抗腫瘍性も獲得している。rhHEPOは特許化されており、近年ではがんと血栓塞栓症の関連性が注目されていることから、その機序や治療を研究する上で重要であると考える。
|
